The feasibility of neoadjuvant high-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with nonmetastatic high grade localized osteosarcoma - Results of a phase II study

被引:21
作者
Arpaci, F
Ataergin, S
Ozet, A
Erler, K
Basbozkurt, M
Ozcan, A
Komurcu, S
Ozturk, B
Celasun, B
Kilic, S
Kuzhan, O
机构
[1] GATA Gulhane Fac Med, Dept Med Oncol & Bone Marrow Transplantat, Ankara, Turkey
[2] GATA Gulhane Fac Med, Dept Orthoped, Ankara, Turkey
[3] GATA Gulhane Fac Med, Dept Pathol, Ankara, Turkey
[4] GATA Gulhane Fac Med, Dept Epidemiol, Ankara, Turkey
关键词
nonmetastatic osteosarcoma; high-dose chemotherapy; limb-sparing surgery; necrosis rate;
D O I
10.1002/cncr.21279
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The primary and secondary objectives of the current study were to improve the >= 90% tumor necrosis rate and assess the toxicity profile of the neoadjuvant high-dose chemotherapy (HDC) regimen, respectively. METHODS. Twenty-two patients with AJCC Stage IIB high-grade osteosarcoma were included in the current study. Two cycles of an induction chemotherapy regimen including cisplatin, doxorubicin, and ifosfamide followed by HDC and autologous peripheral blood stem cell support or transplantation (APBSCT) were given. After engraftment was achieved, the patients underwent limb-sparing surgery (LSS) followed by three to six cycles of postoperative chemotherapy depending on the tumor necrosis rate. RESULTS. The median follow-up, the total duration of treatment, and the time to surgery were 23.7 months, 5.96 months, and 3.03 months, respectively. The necrosis rate was at least 90% in 82% of the cases. The 3-year overall survival (OS) and disease-free survival (DFS) rates were 83% and 70%, respectively. Leukopenia, anemia, thrombocytopenia, nausea and emesis, and mucositis were the most frequent Grade 3 and Grade 4 toxicities (according to the National Cancer Institute Common Toxicity Criteria [version 2.0]) of induction, high-dose, and adjuvant chemotherapies. At the time of last follow-up, no patient had died of chemotherapeutic toxicity. LSS was performed in all patients. Surgery-related complications were reported in 3 of 22 patients. Functional scoring results were excellent in eight patients, good in nine patients, fair in two patients, and poor in three patients. CONCLUSIONS. The results of the current Phase 11 study suggest that neoadjuvant HDC provides a greater than 90% necrosis rate with acceptable toxicity. A short duration of therapy and the feasibility of LSS in all patients are additional advantages of this approach.
引用
收藏
页码:1058 / 1065
页数:8
相关论文
共 35 条
[1]  
[Anonymous], MODIFICATION SYSTEM
[2]   Long-term results after combined modality treatment for non-metastatic osteosarcoma [J].
Aparicio, J ;
Segura, A ;
Montalar, J ;
Garcerá, S ;
Oltra, A ;
Santaballa, A ;
Yuste, A ;
Pastor, M ;
Munárriz, B .
MEDICAL ONCOLOGY, 1999, 16 (04) :255-260
[3]  
ASSI H, 2004, P AN M AM SOC CLIN, V9020, P819
[4]   Predictive factors for local recurrence in osteosarcoma - 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy [J].
Bacci, G ;
Ferrari, S ;
Mercuri, M ;
Bertoni, F ;
Picci, P ;
Manfrini, M ;
Gasbarrini, A ;
Forni, C ;
Cesari, M ;
Campanacci, M .
ACTA ORTHOPAEDICA SCANDINAVICA, 1998, 69 (03) :230-236
[5]   Neoadjuvant chemotherapy for osteosarcoma of the extremity - Intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome [J].
Bacci, G ;
Forni, C ;
Ferrari, S ;
Longhi, A ;
Bertoni, F ;
Mercuri, M ;
Donati, D ;
Capanna, R ;
Bernini, G ;
Briccoli, A ;
Setola, E ;
Versari, M .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2003, 25 (11) :845-853
[6]   A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity [J].
Bacci, G ;
Ferrari, S ;
Tienghi, A ;
Bertoni, F ;
Mercuri, M ;
Longhi, A ;
Fiorentini, G ;
Forni, C ;
Bacchini, P ;
Rimondini, S ;
De Giorgi, U ;
Picci, P .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2001, 27 (01) :98-104
[7]   Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli Osteosarcoma-2 protocol: An updated report [J].
Bacci, G ;
Ferrari, S ;
Bertoni, F ;
Ruggieri, P ;
Picci, P ;
Longhi, A ;
Casadei, R ;
Fabbri, N ;
Forni, C ;
Versari, M ;
Campanacci, M .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (24) :4016-4027
[8]  
BACCI G, 1993, CANCER, V72, P3227, DOI 10.1002/1097-0142(19931201)72:11<3227::AID-CNCR2820721116>3.0.CO
[9]  
2-C
[10]  
Bacci G, 2000, ONCOL REP, V7, P1129